Study of Umbilical Cord Mesenchymal Stem Cell Secretome to Support Cognitive Recovery After Subacute Ischemic Stroke in Adults

What this Trial Is About

Researchers are studying whether adding mesenchymal stem cell-derived secretome to standard stroke care and rehabilitation can improve cognitive recovery in adults who have had a subacute ischemic stroke. This pilot randomized controlled trial includes adults aged 40 to 75 years who experienced an ischemic stroke between 7 days and 3 months prior and have mild-to-moderate cognitive impairment. The study aims to evaluate changes in cognitive function using the Indonesian version of the Montreal Cognitive Assessment. Participants are randomly assigned to one of two groups. One group receives standard medical treatment and standardized stroke rehabilitation plus two doses of umbilical cord mesenchymal stem cell-derived secretome administered on day 1 and day 8. The other group receives the same standard care and rehabilitation without the secretome. Safety is monitored during and after secretome administration to observe for any adverse events. Throughout the study, participants undergo assessments of cognitive, neurological, and functional status, along with electrophysiological and biomarker evaluations at baseline, week 4, and week 8. Researchers measure outcomes including cognitive scores, brain wave patterns, levels of brain-derived neurotrophic factor and interleukin-1 beta in the blood, stroke severity scales, and any treatment-related side effects. The study lasts approximately 8 weeks from baseline to final assessment.

MSC Secretome Therapy for Cognitive Recovery After Subacute Ischemic Stroke